BIBW 2948 BS

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

Bronchitis, ChronicPulmonary Disease, Chronic Obstructive

Phase 2

Effect of BIBW 2948 BS in COPD

CompletedNCT00423137

Boehringer IngelheimBronchitis, Chronic, Pulmonary Disease, Chronic Obstructive

Start: 2007-01-17End: 2008-07-09Updated: 2021-11-19

Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive Bronchitis

WithdrawnNCT00726479

Boehringer IngelheimBronchitis, Chronic, Pulmonary Disease, Chronic Obstructive

Start: 2008-08-31Updated: 2014-03-27

Related Papers

Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary disease.

2009-12-1067 citations